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1 Abstract
2 Background and Aims: The structured, simplified modified Rankin scale questionnaire 
3 (smRSq) may increase reliability over the interrogative approach to scoring the modified 
4 Rankin scale (mRS) in acute stroke research and practice.  During the conduct of the alteplase-
5 dose-arm of the international ENhanced Control of Hypertension ANd Thrombolysis StrokE 
6 stuDy (ENCHANTED), we had an opportunity to compare each of these approaches to 
7 outcome measurement.
8 Methods: Baseline demographic data were recorded together with the National Institutes of 
9 Health Stroke Scale (NIHSS).  Follow-up measures obtained at 90 days included mRS, smRSq, 
10 and the 5-Dimension European Quality of life scale (EQ-5D).  Agreements between smRSq 
11 and mRS were assessed with the Kappa statistic.  Multiple logistic regression was used to 
12 identify baseline predictors of Day 90 smRSq and mRS scores.  Treatment effects, based on 
13 Day 90 smRSq/mRS scores were tested in logistic and ordinal logistic regression models. 
14 Results: SmRSq and mRS scores had good agreement (weighted Kappa 0.79, 95% confidence 
15 interval [CI] 0.78-0.81), whilst variables of age, atrial fibrillation, diabetes mellitus, pre-morbid 
16 mRS (1 vs. 0), baseline NIHSS scores and imaging signs of cerebral ischemia, similarly 
17 predicted their scores.  Odds ratios for death or disability, and ordinal shift, 90 day mRS scores 
18 using smRSq were 1.05 (95% CI 0.91-1.20; one-sided p=0.23 for noninferiority) and 0.98 (95% 
19 CI 0.87-1.11; P=0.02 for noninferiority), similar to those using mRS. 
20 Conclusions: This study demonstrates the utility of the smRSq in a large, ethnically diverse 
21 clinical trial population.  Scoring of the smRSq shows adequate agreement with the standard 
22 mRS, thus confirming it is a reliable, valid and useful alternative measure of functional status 
23 after acute ischemic stroke.
24 Clinical Trial registration URL: http://www.clinicaltrials.gov. Unique identifier: 
25 NCT01422616
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26 Introduction and Aims
27 The modified Rankin scale (mRS) is the most popular assessment tool for measuring overall 
28 functional status in patients who have suffered a stroke or other form of neurological 
29 disability,1 both in clinical practice and research.2, 3  However, due to criticism being raised 
30 over subjectivity in aspects of its categorization/scoring,4 Bruno et al. developed the short, 
31 structured, simplified modified Rankin scale questionnaire (smRSq)5, 6 which has been shown 
32 to correlate with the size of the ischemic lesion,6 health-related quality of life,7 and 
33 neurological severity8 in small single center studies.  The smRSq has also shown good 
34 reliability and validity in Chinese stroke patients.9  However, it has not been validated in a 
35 broader population or in the context of international research where the mRS remains the gold 
36 standard method of outcome assessment.  We aimed to compare scores on the mRS and 
37 smRSq, their predictor variables, their correlation with neurological impairment on the 
38 National Institutes of Health Stroke Scale (NIHSS) and health-related quality of life on the 5-
39 Dimension European Quality of life scale (EQ-5D), and treatment effects using them as 
40 outcome measures, among participants of the alteplase-dose arm of the Enhanced Control of 
41 Hypertension and Thrombolysis Stroke study (ENCHANTED). 
42 Methods
43 Study design
44 ENCHANTED was an international, multicenter, quasi-factorial, prospective, randomized, 
45 open, blinded outcome assessed, clinical trial that assessed the effectiveness of low versus 
46 standard dose intravenous alteplase, and intensive versus guideline-recommended blood 
47 pressure (BP) management, in thrombolysis-eligible patients with acute ischemic stroke, the 
48 details of which are described elsewhere.10, 11  In brief, the first arm of the trial assessed 0.6 
49 mg/kg compared to 0.9 mg/kg alteplase in 3310 patients (age ≥18 years) within 4.5 hours of 
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50 the onset of symptoms and followed up these patients to 90 days.  The primary endpoint was 
51 death or disability defined by scores of 2 to 6 on the mRS.  The trial was approved by local 
52 ethics committees and regulatory bodies, and written informed consent was obtained from the 
53 patient or an appropriate surrogate.  The trial is registered at ClinicalTrials.gov 
54 (NCT01422616). 
55 Measures
56 Demographics, clinical characteristics including the severity of neurological impairment on the 
57 NIHSS, were recorded in participants at the time of enrolment (baseline).  The trial excluded 
58 patients with pre-morbid functional impairment (mRS scores >1) but collected estimated pre-
59 morbid mRS (0 or 1) for those included.  Signs of cerebral ischemia on brain imaging, and any 
60 evidence of proximal vessel occlusion on computed tomographic angiography (CTA) or 
61 magnetic resonance angiography (MRA), were reported by clinicians.  Assessors with a health 
62 professional background (doctors, nurses or scientists) blind to treatment allocation and who 
63 had received in-person and online training (https://secure.trainingcampus.net), recorded mRS 
64 and smRSq scores by telephone or face-to-face interview in patients or a suitable proxy at 28 
65 and 90 days post-randomisation.  These outcome assessors had no mandatory training in the 
66 use of smRSq.  They were advised to first assess patients with the mRS and then immediately 
67 administer the smRSq, as listed on the case report form.  The 7-item mRS covers no symptoms 
68 (score 0), symptoms but no significant disability (1), slight disability (2), moderate disability 
69 (3), moderately severe disability (4), severe disability (5), and death (6).  The smRSq takes on 
70 average 1.7 minutes to administer,7 and represents mRS items through yes/no answers to 5 
71 questions addressing key functional states: living alone without any help from another person 
72 for bathing, toileting, shopping, preparing or getting meals, and managing finances; doing 
73 everything as before the stroke; being back to pre-stroke status; walking without help from 
74 another person; and being bedridden or needing constant supervision.  The EQ-5D, which was 
Page 6 of 22International Journal of Stroke
For Review Only
4
75 also administered directly in a patient or proxy at 28 and 90 days, defines the state of general 
76 health across five dimensions (mobility, self-care, usual activities, pain/discomfort, and 
77 anxiety/depression) with three levels of responses within each dimension (no problems, 
78 some/moderate problems, and severe problems).  The EQ-5D utility score integrates the ratings 
79 of the 5 dimensions into a single score, calculated using population-based preference weights 
80 for each subscale.  The weights used in the present analyses were derived from a study based 
81 on a representative sample of the UK population.12  Utility scores express HRQoL 
82 quantitatively as a fraction of perfect health, with a score of 1 representing perfect health, a 
83 score of 0 representing death, and negative scores (minimum score -0.594) representing health 
84 states considered worse than death.13 
85 Statistical analysis
86 Strength of agreement on ordinal analysis14 of the smRSq and mRS at Day 90 were assessed 
87 through Cohen’s unweighted kappa (K) values of ≤0 (poor), 0.01-0.20 (slight), 0.21-0.40 (fair), 
88 0.41-0.60 (moderate), 0.61-0.80 (substantial), and 0.81-1 (almost perfect), and weighted kappa 
89 (Kw) values of ≤0.20 (poor), 0.21–0.40 (fair), 0.41–0.60 (moderate), 0.61–0.80 (good), and 
90 0.81–1.00 (very good) agreement.15  Multiple logistic regression was used to build prediction 
91 models for scores on the mRS and smRSq at Day 90, and to calculate C-indexes.  Significant 
92 predictors (P<0.05) from the univariate analyses were tested in multiple logistic regression 
93 models for their associations with outcomes.  The non-significant covariates were removed 
94 until all the remaining predictors were statistically significant (P<0.05).  Collinearity between 
95 variables were checked.  Baseline variables included in the models were: age (<65 vs. ≥ 65 
96 years), sex, estimated prestroke function on mRS (0 vs. 1), baseline NIHSS score, history of 
97 atrial fibrillation (AF), diabetes mellitus, hypertension, previous stroke, coronary artery 
98 disease, and hypercholesterolemia, use of aspirin/other antiplatelet agent(s), and warfarin/other 
99 anticoagulation, and visible early ischemic change and proximal vessel occlusion on imaging.  
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100 Correlations between smRSq and mRS at Day 90, and with NIHSS and EQ-5D utility scores 
101 at Day 90, were analyzed using Spearman correlation, with the r coefficient graded as 0.2–0.4 
102 (weak), 0.4–0.7 (moderate), and 0.7–1.0 (strong).  The treatment effects comparing low-dose 
103 alteplase to standard-dose alteplase in the trial were tested using scores derived from smRSq, 
104 to compare with the study results generated using mRS.  The noninferiority margin was 
105 1.14,10,11 that is for the upper boundary of the 95% confidence interval (CI) for the odds ratio 
106 (OR) with low-dose alteplase as compared with standard-dose alteplase, of less than 1.14.  
107 Single logistic regression was used to test and estimate unadjusted OR of death and disability 
108 (mRS 2 to 6).  Multiple logistic regression were used for adjusted OR in intention to treat and 
109 per protocol populations.  For shift analyses of the smRSq scores, ordinal logistic regression 
110 was used.  The variables adjusted in treatment effect analyses include site, time from symptom 
111 onset to randomisation, score as a continuous measure on the NIHSS, age, sex, ethnicity, pre-
112 morbid mRS score (0 or 1), pre-morbid use of aspirin, other antiplatelet agent or warfarin, and 
113 any history of stroke, coronary artery disease, diabetes mellitus and atrial fibrillation (AF).  
114 Testing was undertaken for the degree of agreement between smRSq and mRS at Day 28 using 
115 Kappa (K) and weighted Kappa (Kw), and for the strength of correlations between smRSq or 
116 mRS at Day 28, and NIHSS or EQ-5D utility scores at Day 28, using Spearman correlation 
117 with the r coefficient (Supplementary Appendix).  P values <0.05 were regarded as significant.  
118 SAS enterprise 7.1 was used in all analyses.
119 Data sharing 
120 The authors confirm that the data supporting the findings of this study are available within the 
121 article and/or its supplementary materials.  Individual participant data used in these analyses 
122 can be shared by request from any qualified investigators via the Research Office of The 
123 George Institute for Global Health, Australia.
124 Results
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125 There were 3204 acute ischemic stroke patients with NIHSS scores recorded at baseline, and 
126 mRS, smRSq and EQ-5D scores recorded at Day 90.  Agreement between smRSq and mRS 
127 scores occurred in 2051 (64%) patients (Supp Table 1, Figure 1), and overall was moderate-
128 good (K 0.57, 95% CI 0.55–0.59, and Kw 0.79, 95% CI 0.78–0.81).  
129 Supplementary Table 2 shows the variables remained in the prediction models were common 
130 to both the smRSq and mRS at Day 90 after successively removing non-significant covariates; 
131 these included age (>65 years), AF, diabetes mellitus, pre-morbid symptoms, NIHSS scores 
132 and signs of cerebral ischemia on imaging.  C-indexes for the model fit were similar for the 
133 smRSq and mRS (0.74, 95% CI 0.72-0.76, and 0.75, 95% CI 0.73-0.77, mRS, respectively) 
134 (Figure 2). 
135 Concordance was also evident for baseline NIHSS scores (positive correlation; r 0.442, 
136 P<0.0001 and r 0.455, P <0.0001, respectively) and EQ-5D utility score (negative correlation; 
137 r -0.836, P<0.0001, and r -0.874, P <0.0001, respectively) and smRSq and mRS at Day 90.
138 Comparisons of the treatment effects using smRSq and mRS are presented in Supp. Table 3.  
139 Both the dichotomous and ordinal outcomes using smRSq were similar to the outcomes from 
140 mRS.  The unadjusted dichotomous outcome (score of smRSq 2 to 6), which was used to 
141 compare with the primary outcome of the alteplase-dose arm of the trial (OR 1.09, 95% CI 
142 0.95-1.25; one sided P=0.51 for noninferiority), occurred in 886 of 1609 patients (55.1%) in 
143 the low-dose group and in 863 of 1600 patients (53.9%) in the standard-dose group (OR 1.05, 
144 95% CI 0.91-1.20; one-sided P=0.23 for noninferiority).  In the unadjusted shift analysis on 
145 smRSq scores comparing low-dose alteplase to standard-dose alteplase, the OR was 0.98 
146 (95% CI 0.87-1.11; P=0.02 for noninferiority) similar to that for mRS shift scores (OR 1.0; 
147 95% CI 0.89-1.13; P=0.04 for noninferiority).
148 The results for agreement between smRSq and mRS at Day 28, and correlations with NIHSS 
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149 and EQ-5D utility score at Day 28, are included in the supplementary appendix. 
150 Discussion
151 Our study validates the smRSq as a suitable stroke outcome measure by showing comparable 
152 scoring to the conventional mRS, similar level of moderate-strong correlations with the NIHSS 
153 and EQ-5D, common predictor variables and similar treatment effects when used as trial 
154 outcome. 
155 Dennis et al.3 showed similar agreement between the mRS and smRSq using postal or 
156 telephone assessment in 225 participants, whilst Yuan et al.9 found a higher degree of overall 
157 agreement than we have shown in their study of 150 Chinese patients.  The factors identified 
158 in our predictive models for the smRSq and mRS support other outcome studies.16, 17  For 
159 example, in a multivariable analysis by Wahlgren et al.,16 older age, high blood glucose, high 
160 NIHSS, and infarction on brain imaging were found to predict poor outcome (mortality or 
161 dependency) in patients treated with intravenous alteplase, whilst pre-stroke disability was only 
162 associated with mortality.  Baseline severity, history of diabetes mellitus, ischemic stroke, and 
163 peripheral artery disease have also been reported to predict recovery after disabling ischemic 
164 stroke.17  Katzan et al.18 showed only a moderate correlation (r=-0.53, p<0.01) between the 
165 mRS and EQ-5D utility score, possibly due to the greater number of patients with mRS scores 
166 of 0-2 (75%), which has shown a lower correlation with EQ-5D19, than in the ENCHANTED10 
167 (~65%).  Another study showed the smRSq had moderate correlation with the physical (r=0.50, 
168 P=0.005) but only slight correlation with the mental components (r=0.36, P=0.048) of the 12-
169 item short form questionnaire.5  
170 More severe strokes (NIHSS scores >10) are associated with higher mRS scores at hospital 
171 discharge.20 NIHSS scores at Day 2 are a good predictor of mRS scores >3 at 90 days.21  In a 
172 study of acute ischemic stroke patients treated with mechanical thrombectomy, NIHSS scores 
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173 at baseline and hospital discharge were each significantly associated with 90-day mRS scores.22  
174 Another study has shown a similar moderate level of correlation between initial NIHSS and 
175 Day 90 smRSq scores (r = 0.69, R2 = 0.47, P < 0.001)5 to our study. 
176 The smRSq appears easy to administer and automatically calculates a final score from the 
177 structured responses to five questions, whereas the mRS often requires the assessor to make a 
178 judgment call in deciding which category best fits a certain grading of disability or level of 
179 dependency.  While training in the use of the mRS is often used to decrease error, this can be 
180 resource intensive for large studies.  It is interesting to note that a high percentage of patients 
181 who scored 1 or 2 on the mRS scored 3 on smRSq in our study.  One explanation could be that 
182 a high proportion of ENCHANTED patients experienced acalculia and difficulty managing 
183 finances without major motor disability after suffering a left middle cerebral artery stroke.  This 
184 may have resulted in them answering negatively the first question of the smRSq, resulting in a 
185 score ≥3.  Another explanation is broader cognitive impairment but we did not collect such 
186 information in the study. 
187 Our analyses found that similar factors were predictors of smRSq and mRS.  This confirms the 
188 good correlation between the two scales and re-enforces that they are well-known predictors 
189 of poor outcome.  Similarly, the correlation between smRSq and mRS is good which is not 
190 surprising as both scales correlated similarly with the NIHSS and EQ-5D. 
191 In reviewing the treatment effects of the alteplase-dose arm of ENCHANTED, use of the 
192 smRSq similarly failed to show that low-dose alteplase was noninferior to standard-dose 
193 alteplase with respect to death or disability at Day 90, but was non-inferior with respect to 
194 ordinal shift of smRSq scores, which is consistent with those results using mRS.10  This again 
195 reflects good correlation between the two measures, and for the smRSq to provide a comparable 
196 assessment of a treatment effect to that on the mRS.
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197 Strengths of this study is the large database of prospectively and systematically assessed 
198 patients from a variety of countries and ethnic backgrounds.  There are some limitations 
199 including that these were post-hoc analyses and that the same outcome assessors rated the mRS 
200 and smRSq.  However, the Day 90 assessment case report form was structured for sequential 
201 recording of the mRS followed by smRSq, and these people were not provided with scoring 
202 answers to the smRSq questions.  Another issue is that as patients with pre-morbid functional 
203 impairment/disability (mRS >1) were excluded from the trial, we are unable to provide an 
204 assessment of any influence of this factor on the correlation between the measures.  Moreover, 
205 the finding of large proportion of patients in the score of 3 using smRSq, similarly shown in 
206 the FOCUS trial,23 suggests distribution of patients across categories may differ between mRS 
207 and smRSq, which potentially influenced the results of this study.  Finally, as this work pertains 
208 to a clinical trial involving acute ischemic stroke patients of predominantly mild-moderate 
209 severity, caution may be required in generalizing these results to a more severe patient 
210 population or in those with acute intracerebral hemorrhage.
211 In summary, our study has shown that the smRSq has comparable scoring and construct to the 
212 conventional mRS, and provides a useful, reliable and valid outcome measure in the assessment 
213 of patients with acute ischemic stroke.
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Table 1.  Correlation between smRSq and mRS scores at Day 90
mRS denotes modified Rankin Scale, smRSq simplified modified Rankin Scale questionnaire. 
Kappa statistic 0.57 (95% confidence interval [CI] 0.55–0.59) and weighted Kappa statistic 0.79 (95% CI 0.78–0.81)
*3310 patients were randomized into the alteplase-dose arm, of which 13 were excluded; another 93 patients were excluded from these analyses 
due to missing mRS or smRSq data. 
mRS smRSq
0 1 2 3 4 5 6 Total
0 704 (88.0) 42 (5.3) 11 (1.3) 42 (5.3) 1 (0.1) - - 800
1 311 (42.4) 266 (36.3) 56 (7.6) 97 (13.2) 3 (0.4) - - 733
2 38 (8.0) 75 (15.8) 167 (35.2) 174 (36.6) 16 (3.4) 5 (1.1) - 475
3 6 (1.5) 8 (2.0) 22 (5.6) 285 (72.7) 52 (13.3) 19 (4.6) - 392
4 5 (1.6) 2 (0.6) 2 (0.6) 36 (11.3) 162 (50.9) 111 (34.9) - 318
5 2 (1.1) - - 2 (1.1) 15 (8.5) 157 (89.2) - 176
6 - - - - - - 310 (100) 310
Total 1066 393 258 636 249 292 310 3204*
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Table 2. Independent predictors of smRSq and mRS at Day 90
smRSq 
(C=0.740, 95% CI 0.723-0.757)
mRS 
(C=0.751, 95% CI 0.734-0.767)
Variable OR 95% CI p Value OR 95% CI p Value
Age >65 1.47 1.26-1.71 <0.0001 1.33 1.13-1.56 0.0005
Atrial fibrillation 1.43 1.16-1.77 0.0009 1.29 1.04-1.59 0.019
Diabetes mellitus 1.25 1.03-1.51 0.0245 1.37 1.13-1.66 0.002
Pre-stroke grade of physical function* 2.21 1.79-2.72 <0.0001 2.24 1.82-2.77 <0.0001
NIHSS 1.14 1.12-1.16 <0.0001 1.16 1.14-1.17 <0.0001
Signs of cerebral ischemia on imaging 1.56 1.30-1.88 <0.0001 1.42 1.18-1.71 0.0002
C denotes Concordance Index, CI confidence interval, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, OR odds 
ratio, smRSq simplified modified Rankin Scale questionnaire
*pre-morbid estimated level of physical function with symptoms, based on a score of 1 on the mRS; the comparison was 1 vs. 0
Significant predictors (P<0.05) from the univariate analyses which were tested in multiple logistic regression models were: sex, history of 
hypertension, previous stroke, coronary artery disease, hypercholesterolemia, use of aspirin/other antiplatelet agent(s), use of warfarin/other 
anticoagulation and proximal vessel occlusion.  Significance level of stay in the models was P <0.05.
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Table 3. Comparison of treatment effects using mRS and smRSq in the alteplase-dose arm of the ENCHANTED trial 
smRSq mRS 
Outcome OR 95% CI P value* OR 95% CI P value*
Death or disability: scores 2 to 6†
   Unadjusted 1.05 0.91-1.20 0.23 1.09 0.95-1.25 0.51
   Adjusted† 1.06 0.91-1.23 0.34 1.13 0.97-1.31 0.88
   Adjusted in per protocol population§ 1.05 0.89-1.23 0.30 1.13 0.96-1.32 0.89
Shift analyses of scores 0 to 6‡
   Unadjusted 0.98 0.87-1.11 0.02 1.00 0.89-1.13 0.04
   Adjusted‡ 0.97 0.85-1.10 0.01 0.99 0.88-1.13 0.03
   Adjusted in per protocol population§ 0.95 0.84-1.09 0.01 1.00 0.88-1.14 0.05
CI denotes confidence interval, mRS modified Rankin Scale, OR odds ratio, smRSq simplified modified Rankin Scale questionnaire
*Noninferiority margin was 1.14 (i.e. an upper boundary of the 95% CI for the OR with low-dose alteplase as compared with standard-dose 
alteplase of less than 1.14).
†ORs were estimated from logistic regression models.  Each OR indicates the odds of death or disability (mRS 2 to 6). An OR greater than 1 
favors standard-dose alteplase.  Adjustment for site, time from stroke onset to randomisation, score as a continuous measure on the National 
Institutes of Health stroke scale (NIHSS), age, sex, ethnicity, pre-morbid score of 0 or 1 on the mRS, pre-morbid use of aspirin, other antiplatelet 
agent or warfarin, and any history of stroke, coronary artery disease, diabetes mellitus and atrial fibrillation.
‡ORs were estimated from ordinal logistic regression models. Each OR indicates the odds of an increase of 1 in the mRS score.  An OR greater 
than 1 favors standard-dose alteplase.  Adjustment for same variables as in logistic regression models above.
§Per protocol population excluded patients who have one or more of the following protocol violations: age <18 years; final diagnosis not acute 
ischemic stroke; final diagnosis unknown/uncertain because of missing source documents or neuroimaging; baseline systolic blood 
pressure >185 mmHg; randomized >4.5 hours; failure to receive alteplase at either the correct bolus or infusion dose; failure to obtain a blind 
assessment of the 90-day outcome.
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Figures legend
Figure 1. Bubble plot of agreement between smRSq and mRS at Day 90.  Area of bubbles 
represent the count at each score. 
Figure 2.  ROC curves for predictive models of mRS and smRSq at Day 90. 
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Figure 1.  Agreement between smRSq and mRS at Day 90
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Figure 2.  ROC curves for the predictive models of mRS and smRSq at Day 90
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